Select a Community
Are you sure you want to trigger topic in your Anconeus AI algorithm?
You are done for today with this topic.
Would you like to start learning session with this topic items scheduled for future?
Basic metabolic panel and thyroid stimulating hormone
67%
2/3
Liver function tests and thyroid stimulating hormone
33%
1/3
Iron studies and liver function tests
0%
0/3
Iron studies and thyroid stimulating hormone
Basic metabolic panel and liver function tests
Select Answer to see Preferred Response
This patient has bipolar disorder, for which lithium is first line therapy. Baseline thyroid stimulating hormone (TSH) and basic metabolic panel (BMP) should be checked before initiating lithium, because of the risk of hypothyroidism and nephrotoxicity (Illustration A). The patient meets the diagnostic criteria for Bipolar I (an episode of mania with or without episodes of depression), where mania is defined by having 3 of the following: grandiosity, decreased need for sleep, pressured speech, flight of ideas, distractibility, increase in goal-oriented activity, psychomotor agitation, and hedonism. Lithium, which is a first line therapy for bipolar disorder, is notorious for having a narrow therapeutic window. Side effects include: tremor, sedation, acne, heart block, hypothyroidism, nephrogenic diabetes insipidus, leukocytosis, and Ebstein anomaly in developing fetuses if given during pregnancy (illustration B). Coingestion of thiazide diuretics, NSAIDs, and ACE-inhibitors increases the risk of these side effects. Incorrect answers: Answers 2-5: Lithium is not associated with hepatic toxicity or impaired iron metabolism.
5.0
(1)
Please Login to add comment